Barclays
KLRS

Barclays’s Kalaris Therapeutics KLRS Stock Holding History

Barclays’s Portfolio KLRS Stock Details KLRS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.23K Sell
303
-4,977
-94% -$25.9K ﹤0.01% 4914
2026
Q1 		$30.5K Sell
5,280
-785
-13% -$6.97K ﹤0.01% 4471
2025
Q4 		$51.2K Buy
+6,065
New +$38.8K ﹤0.01% 4738
2025
Q2 		– Sell
-1
Closed -$8 – 5639
2025
Q1 		$8 Buy
+1
New +$10 ﹤0.01% 5185
2024
Q2 		– Sell
-1,532
Closed -$26.6K – 5392
2024
Q1 		$26.6K Sell
1,532
-1,496
-49% -$24.4K ﹤0.01% 4721
2023
Q4 		$47.3K Buy
3,028
+2,219
+274% +$87.5K ﹤0.01% 4781
2023
Q3 		$40K Buy
809
+2
+0.2% +$136 ﹤0.01% 3956
2023
Q2 		$63.1K Sell
807
-742
-48% -$70.5K ﹤0.01% 3742
2023
Q1 		$140K Buy
1,549
+323
+26% +$41.1K ﹤0.01% 3990
2022
Q4 		$145K Buy
1,226
+305
+33% +$51.7K ﹤0.01% 4016
2022
Q3 		$167K Sell
921
-2,358
-72% -$367K ﹤0.01% 3304
2022
Q2 		$294K Buy
3,279
+2,435
+289% +$255K ﹤0.01% 3209
2022
Q1 		$131K Buy
+844
New +$168K ﹤0.01% 3665

Other funds holding KLRS

SB
Samsara BioCapital Palo Alto, California $1.22B AUM 242.83% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $38.9B AUM 28.51% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
IC
Ikarian Capital Dallas, Texas $928M AUM 596.14% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Barclays's KLRS Position: Q2 2026 in Review

Barclays reduced its Kalaris Therapeutics (KLRS) stake by 94% in Q2 2026, selling an estimated $25.9K and leaving 303 shares worth $1.23K. The position accounts for ﹤0.01% of the portfolio, ranked #4914.

Barclays first reported a position in KLRS in Q1 2022 and has held it in 13 quarters since. The position peaked at $294K in Q2 2022. 56 funds tracked by Wall St. Rank hold KLRS as of Q2 2026.

  • Barclays held 303 shares of Kalaris Therapeutics worth $1.23K as of Q2 2026.
  • Barclays sold 4,977 Kalaris Therapeutics shares in Q2 2026, an estimated $25.9K.
  • Kalaris Therapeutics made up ﹤0.01% of Barclays's portfolio in Q2 2026, its #4914 holding.
  • Barclays first reported a position in Kalaris Therapeutics in Q1 2022 and has held it in 13 quarters since.
  • Barclays's Kalaris Therapeutics position peaked at $294K in Q2 2022.
  • 56 funds tracked by Wall St. Rank held Kalaris Therapeutics as of Q2 2026.

Based on Barclays's 13F filing for Q2 2026, filed 14 Aug 2026.